Drugs / TAA05 cell injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05017883 | Jul 2021 → Oct 2023 | acute myeloid leukemia | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAA05 cell injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05017883 ↗ |
| Action | Deplete | “use the patient's own immune cells to clear cancer cells.” NCT05017883 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor T cells (car-t)” NCT05017883 ↗ |